SCHEDULE: Commodore Capital Discloses 9.9% Stake in Karyopharm

Commodore Capital LP and its principals have reported a 9.9% beneficial ownership stake in Karyopharm Therapeutics Inc.

Summary

• Commodore Capital LP, Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz filed a Schedule 13G.
• The reporting persons collectively beneficially own 1,950,000 shares of Karyopharm Therapeutics Inc. common stock.
• This holding represents 9.9% of the issuer's total outstanding common stock, based on 19,618,032 shares reported as of March 23, 2026.
• The filing confirms the shares are held for investment purposes and not to influence or change control of the company.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive development, as it reflects institutional interest in the stock without indicating immediate corporate governance changes.

Positives

• Institutional investor confidence indicated by a significant 9.9% equity position.
• The filing confirms the investment is passive, suggesting no immediate activist pressure on management.

Negatives

• None identified in this regulatory disclosure.

Risks

• Concentration of ownership by a single investment firm could lead to increased share price volatility if the firm decides to divest.
• Reliance on the accuracy of the issuer's reported outstanding share count for percentage calculations.

Future Outlook

The filing does not provide forward-looking guidance for the company, as it is a disclosure of beneficial ownership.

Industry Context

StockSavvy.ai notes that institutional accumulation in small-cap biotech firms like Karyopharm often signals market confidence in the company's clinical pipeline or potential for strategic partnerships.

Comparison to Industry Standards

• The 9.9% stake is a standard threshold for institutional investors to report under Schedule 13G to avoid the more stringent requirements of Schedule 13D.
• The passive nature of the investment is consistent with typical hedge fund portfolio management strategies in the biotechnology sector.

Stakeholder Impact

• Shareholders may view the entry of a significant institutional investor as a validation of the company's long-term value proposition.

Next Steps

• The reporting persons are required to file amendments to this statement if there are any material changes in the percentage of shares owned.

Key Dates

Keywords

Karyopharm Therapeutics, Commodore Capital, Schedule 13G, Beneficial Ownership, Biotech Investment, Equity Disclosure